Novo Nordisk A/S (NYSE:NVO) Stock Price Up 0.4%

Shares of Novo Nordisk A/S (NYSE:NVO) traded up 0.4% on Monday . The company traded as high as $123.77 and last traded at $123.50. 1,512,707 shares changed hands during trading, a decline of 69% from the average session volume of 4,823,959 shares. The stock had previously closed at $123.05.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on NVO shares. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price target for the company. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Finally, UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Stock Down 0.5 %

The firm’s 50 day simple moving average is $127.33 and its 200-day simple moving average is $113.50. The company has a market cap of $568.61 billion, a price-to-earnings ratio of 43.69, a P/E/G ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Institutional Trading of Novo Nordisk A/S

A number of large investors have recently made changes to their positions in the company. Xponance Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at $248,000. Bank of New York Mellon Corp raised its holdings in shares of Novo Nordisk A/S by 97.1% in the third quarter. Bank of New York Mellon Corp now owns 863,598 shares of the company’s stock valued at $78,536,000 after buying an additional 425,392 shares during the last quarter. Baystate Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S by 260.9% during the third quarter. Baystate Wealth Management LLC now owns 581 shares of the company’s stock worth $53,000 after buying an additional 420 shares during the period. Waldron Private Wealth LLC purchased a new position in shares of Novo Nordisk A/S during the third quarter worth about $213,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Novo Nordisk A/S by 118.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 190,605 shares of the company’s stock valued at $17,334,000 after acquiring an additional 103,545 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.